Packaging solutions for Type 2 diabetes treatment
Primary packaging solutions for GLP-1 diabetes treatment
SCHOTT Pharma offers a wide range of drug containment and drug delivery solutions for Type 2 diabetes (T2D) management, enabling pharmaceutical companies to focus on drug development while leaving drug-container interaction, shelf life, and administration to us.
Sensitive GLP-1-based drugs such as GLP-1 RA peptides require advanced filling, storage and administration solutions for effective and safe insulin therapy for T2D. With a long history of pharmaceutical packaging, SCHOTT Pharma is your reliable partner for GLP-1 based therapies, offering a variety of packaging solutions for Type 2 diabetes treatment.
An alternative to insulin
The landscape of T2D therapies has evolved significantly over the past century. Traditional insulin therapies have long been a cornerstone in managing blood glucose levels for patients with Type 2 diabetes. However, medical advances have introduced a new generation of GLP-1–based therapies that expand treatment possibilities.These diabetic medicine advancements complement and, in some cases, reduce reliance on traditional insulin treatments by offering greater flexibility and improved glycemic control. GLP-1–based drugs mimic the action of natural incretin hormones to stimulate insulin secretion and regulate blood glucose levels. At the same time, continued innovation in delivery systems, including the injection devices for insulin, supports safe and convenient self-administration for patients.
As global demand for GLP-1 therapies continues to rise, ensuring a reliable supply of primary packaging, seamless production processes, and safe, user-friendly self-administration solutions becomes increasingly critical.
The ideal container for your GLP-1 diabetes treatment
Drugs to treat Type 2 diabetes are continually being improved and updated, but they all consist of tiny molecules that need to be stored safely from the point of filling until administration. Whether it’s GLP-1 RA drugs or the new generation of GLP-1-based medication, safe storage is vital for effectiveness and patient safety. SCHOTT Pharma is proud to offer a broad range of potential packaging solutions for Type 2 diabetes treatment, tailored to your individual needs.
Syringes
Cartridges
Vials
Supporting you during the regulatory registration process
After choosing your ideal drug containment or drug delivery solution, SCHOTT Pharma supports you throughout your regulatory registration process. We take care your selected product has regulatory availability in all countries where you intend to go to market. Different countries follow different registration processes, we will prepare you and your product to meet compliance with the respective international norms and standards, as well as country-specific laws and guidelines
Strong compatibility
SCHOTT Pharma prioritizes patient convenience and accessibility, with all drug delivery solutions engineered to facilitate easy and precise drug administration. Strong compatibility ensures that they work seamlessly with a wide range of injection devices, whether it’s off-the-shelf pen injectors, auto injectors, or several other devices.We understand the importance of patient confidence and safety in drug self-administration, and our commitment to compatibility reflects our dedication to enhancing the overall patient experience.
Smooth fill-and-finish
SCHOTT Pharma recognizes the importance of efficient fill-and-finish operations and offers containment solutions that are designed for ease and simplicity. This minimizes downtime and drug waste. We also closely collaborate with the world’s leading fill-and-finish machine manufacturers to ensure smooth operation.With options for both standard bulk filling and ready-to-use filling, our flexibility optimizes your pharmaceutical production while maintaining the highest standards of quality and efficiency.
Sustainable solutions for large-scale drug manufacturing and packaging
In any large-scale manufacturing operation, sustainable drug containment solutions and compliant waste management are important issues. SCHOTT Pharma provides integrated environmental approaches in our product and service solutions and will support all customers in managing sustainability compliance within their supply chain. This includes:
- Services to facilitate customer reviews of SCHOTT Pharma’s sustainability performance and assessment of the product carbon footprint (PCF).
- A sustainable procurement program using the third-party rating platform EcoVadis, providing quick and easy access to standardized information about our sustainability performance.
- Product-specific carbon footprint assessment projects to promote the collaborative understanding of the emission contributions of your containment solution.
SCHOTT Pharma Containers made from FIOLAX® Pro glass tubing – a pharmaceutical glass to be produced in an electric melting tank. This switch in glass melting technology plus the usage of green electricity can save e.g. up to 50% CO2 emissions of a 10ml vial.
Get in touch
Florence Buscke